AR and prostate carcinoma: Alterations in AR signaling, which include AR amplification and mutations that lead to increased AR activity and AR activation by an outlaw pathway in a ligand-independent manner, are important mechanisms that drive prostate cancer survival and progression to castration-resistant prostate cancer (CRPC) [2].